Global KRAS Inhibitor Market Growth 2024-2030

Global KRAS Inhibitor Market Growth 2024-2030

KRAS inhibitors are a class of targeted cancer therapies designed to block the activity of the KRAS protein, a common driver of cancer, particularly in pancreatic, colorectal, and lung cancers. KRAS mutations are notoriously difficult to target because the protein has a smooth surface with few pockets for drug binding. However, recent advances have led to the development of specific inhibitors, such as sotorasib and adagrasib, which target the G12C mutation in KRAS, a mutation present in a subset of cancers. These inhibitors work by irreversibly binding to the mutant KRAS protein, preventing it from signaling the uncontrolled cell growth that leads to cancer. While these drugs have shown promise, they are not universally effective, and resistance often develops, leading to ongoing research to improve their efficacy and expand their use to other KRAS mutations.

The global KRAS Inhibitor market size is projected to grow from US$ 131 million in 2024 to US$ 215 million in 2030; it is expected to grow at a CAGR of 8.6% from 2024 to 2030.

LP Information, Inc. (LPI) ' newest research report, the “KRAS Inhibitor Industry Forecast” looks at past sales and reviews total world KRAS Inhibitor sales in 2023, providing a comprehensive analysis by region and market sector of projected KRAS Inhibitor sales for 2024 through 2030. With KRAS Inhibitor sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world KRAS Inhibitor industry.

This Insight Report provides a comprehensive analysis of the global KRAS Inhibitor landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on KRAS Inhibitor portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global KRAS Inhibitor market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for KRAS Inhibitor and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global KRAS Inhibitor.

United States market for KRAS Inhibitor is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for KRAS Inhibitor is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for KRAS Inhibitor is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key KRAS Inhibitor players cover Amgen, Boehringer Ingelheim, BridgeBio Pharma, Erasca, Innovent Biologics, etc. In terms of revenue, the global two largest companies occupied for a share nearly

% in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of KRAS Inhibitor market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
Lung Cancer
Pancreatic Cancer
Colorectal Cancer
Others

Segmentation by Application:
Clinic Laboratories
Cancer Diagnostic Centres
Hospitals
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Amgen
Boehringer Ingelheim
BridgeBio Pharma
Erasca
Innovent Biologics
Incyte
Mirati Therapeutics
Novartis
Jemincare
Cardiff Oncology

Key Questions Addressed in this Report

What is the 10-year outlook for the global KRAS Inhibitor market?

What factors are driving KRAS Inhibitor market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do KRAS Inhibitor market opportunities vary by end market size?

How does KRAS Inhibitor break out by Type, by Application?

Please note: The report will take approximately 2 business days to prepare and deliver.